Goldman Sachs’s Peak Bio, Inc. Common Stock PKBO Stock Holding History

Goldman Sachs’s Portfolio PKBO Stock Details PKBO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-13,716	Closed	-$57.5K	–	6501
2022 Q4	$57.5K	Sell	13,716 -5,712	-29%	-$39.7K	﹤0.01%	5578
2022 Q3	$194K	Sell	19,428 -8,000	-29%	-$79.4K	﹤0.01%	5501
2022 Q2	$270K	Hold	27,428	–	–	﹤0.01%	5487
2022 Q1	$270K	Buy	27,428 +3,276	+14%	+$32.1K	﹤0.01%	5720
2021 Q4	$235K	Hold	24,152	–	–	﹤0.01%	5810
2021 Q3	$236K	Buy	+24,152	New	+$234K	﹤0.01%	5639

Other funds holding PKBO

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Goldman Sachs's PKBO Position: Q1 2023 in Review

Goldman Sachs sold out of Peak Bio, Inc. Common Stock (PKBO) in Q1 2023, closing a stake of 13,716 shares — an estimated $57.5K sold.

Goldman Sachs first reported a position in PKBO in Q3 2021 and held it in 6 quarters. The position peaked at $270K in Q2 2022. 1 fund tracked by Wall St. Rank holds PKBO as of Q1 2023.

Goldman Sachs reported no remaining Peak Bio, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
Goldman Sachs sold 13,716 Peak Bio, Inc. Common Stock shares in Q1 2023, an estimated $57.5K.
Goldman Sachs first reported a position in Peak Bio, Inc. Common Stock in Q3 2021 and held it in 6 quarters.
Goldman Sachs's Peak Bio, Inc. Common Stock position peaked at $270K in Q2 2022.
1 fund tracked by Wall St. Rank held Peak Bio, Inc. Common Stock as of Q1 2023.

Based on Goldman Sachs's 13F filing for Q1 2023, filed 11 May 2023.